Larimar Therapeutics, Inc.
LRMRHealthcare|Biotechnology|US
$2.39
+0.07 (+3.02%)
DCF Value
$1.06
Tangible Book / Share
$1.23
Cash / Share
$1.50
Clinical Trials (8)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07778836 A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia | Friedreich Ataxia, Friedreich's Ataxia | P3 | Recruiting | 150 | RCT, Double-blind | Nomlabofusp, Placebo |
| NCT06447025 An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia | Friedreich Ataxia | P2 | Recruiting | 85 | Open-label | CTI-1601 |
| NCT05579691 A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia | Friedreich Ataxia | P2 | Completed | 28 | RCT, Double-blind | CTI-1601 |
| NCT04176991 Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia | Friedreich Ataxia | P1 | Completed | 28 | RCT, Double-blind | CTI-1601, Placebo |
| NCT04519567 Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia | Friedreich Ataxia | P1 | Completed | 27 | RCT, Double-blind | CTI-1601, Placebo |
| NCT06681766 A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia | Friedreich Ataxia | P1 | Terminated | 18 | RCT, Double-blind | Nomlabofusp, Placebo |
| NCT05028764 Determine Range of Tissue Frataxin Concentrations and Other Potential Biomarkers | Friedreich Ataxia, Healthy Volunteers | Completed | 60 | — | — | |
| NCT04255680 A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia | Friedreich Ataxia | Completed | 20 | — | — |